More than half of patients scored as hostile; hostility predicts all-cause mortality but not ACS recurrence.
The risk of death is much higher than that of kidney failure among patients with stage 4 chronic kidney disease who are aged 75 years or older.
Significant reductions in risk seen for MI, fatal MI, and coronary heart disease events and mortality.
The effect of empagliflozin on all-cause mortality and hospitalization for heart failure will be evaluated in the in phase 3 EMPACT-MI study.
Predictive value for coronary heart disease risk similar across sex and racial groups.
Compared with children starting dialysis in 1995, those starting dialysis after 2006 had a significant 26% decreased risk of dying from cardiovascular causes in adjusted analyses.
In adults with diabetes, high CAC score predicts CVD, total mortality more strongly in women than in men.
Mortality, incidence of hospital admission for heart failure lower in ≥80s with invasive management.
Five antihypertensive drug classes were analyzed separately and were also compared to all other treatment groups, including placebo.
Two-year gap in life expectancy still exists, compared to individuals without atrial fibrillation.